Personal information

Emails & domains

Verified email domains

Websites & social links

https://www.gla.ac.uk/researchinstitutes/icams/staff/stuartnicklin/

Keywords

gene therapy, viral vectors, adenovirus, renin angiotensin system, cardiovascular

Countries

United Kingdom

Activities

Collapse all

Employment (6)

University of Glasgow: Glasgow, Glasgow, GB

2017-01-08 to present | Professor of Cardiovascular Molecular Therapy (Institute of Cardiovascular & Medical Sciences)
Employment
Source: Self-asserted source
Stuart Nicklin

University of Glasgow: Glasgow, Glasgow, GB

2012-08-01 to 2017-07-31 | Reader (Institute of Cardiovascular & Medical Sciences)
Employment
Source: Self-asserted source
Stuart Nicklin

University of Glasgow: Glasgow, Glasgow, GB

2010-08-01 to 2012-07-31 | Senior Lecturer (Institute of Cardiovascular & Medical Sciences)
Employment
Source: Self-asserted source
Stuart Nicklin

University of Glasgow: Glasgow, Glasgow, GB

2005-02-01 to 2010-07-31 | Lecturer (Institute of Cardiovascular & Medical Sciences)
Employment
Source: Self-asserted source
Stuart Nicklin

University of Glasgow: Glasgow, Glasgow, GB

2003-02-01 to 2005-01-31 | British Heart Foundation Intermediate Research Fellow (Medicine & Therapeutics)
Employment
Source: Self-asserted source
Stuart Nicklin

University of Glasgow: Glasgow, Glasgow, GB

2000-02-01 to 2003-01-31 | Post-doctoral Research Assistant (Medicine & Therapeutics)
Employment
Source: Self-asserted source
Stuart Nicklin

Education and qualifications (3)

University of Glasgow: Glasgow, Glasgow, GB

2005-10-01 to 2007-04-30 | Postgraduate Certificate in Academic Practice (Institute of Cardiovascular & Medical Sciences)
Education
Source: Self-asserted source
Stuart Nicklin

University of Bristol: Bristol, Bristol, GB

1996-10-01 to 2000-03-01 | PhD (Bristol Heart Institute)
Education
Source: Self-asserted source
Stuart Nicklin

University of the West of England Bristol: Bristol, Bristol, GB

1992-09-01 to 1996-06-30 | BSc[Hons] Applied Biological Sciences
Education
Source: Self-asserted source
Stuart Nicklin

Professional activities (1)

British Society for Gene and Cell Therapy: London, GB

2001-01-01 to present
Membership
Source: Self-asserted source
Stuart Nicklin

Funding (16)

Cardiac gene therapy with angiotensin-(1-9): dissecting the underlying mechanism for preservation of cardiac function post-myocardial infarction

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

INVESTIGATING THE ROLE OF RUNX1 IN THE HEART POST-MYOCARDIAL INFARCTION

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

Adenovirus and coagulation factor interactions and the impact on virus stability and utility for gene therapy

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

Adenovirus and coagulation factor interactions and the impact on virus stability and utility for gene therapy

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

Angiotensin-(1-7) and angiotensin-(1-9): assessment as therapeutic targets in acute vascular injury and remodelling

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

Developmental Clinical Studies - Gene Therapy For Vein Graft Failure

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

Refinement and assessment of a novel adenovirus targeting platform for application to human gene therapy

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

Improved adenoviral gene therapy vectors via combined genetic modification of the adenovirus capsid to ablate interaction with blood coagulation facto

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

Dissecting the mechanism of action of the renin angiotensin hormone angiotensin1-9

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

Interrogation of the adenovirus hexon: A new paradigm for virus biology and application to therapeutic gene delivery

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

Development of efficient disease-regulated expression cassettes for gene therapy using microRNA targeting sequences

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

The role of vitamin K-dependent coagulation zymogens in adenovirus dissemeination and pharmacodynamics in vivo.

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

The role of vitamin K-dependent coagulation zymogens in adenovirus dissemination and pharmacodynamics in vivo.

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

Evaluating the impact of coagulation factors on gene delivery using pseudotyped adenoviruses: receptor usage bioavailability and immunogenicity

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

Angiotensin 1-9 and angiotensin 1-7; assessment of their mechanisms of action as counter-regulatory renin angiotensin system peptides in cardiovascular disease

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

Regulated expression of putative therapeutic genes in a model of human essential hypertension

Source: Self-asserted source
Stuart Nicklin via DimensionsWizard

Peer review (1 review for 1 publication/grant)

Review activity for Gene therapy. (1)
How many people are using ORCID?